The catalytic subunits of class I PI3Ks comprise four isoforms: p110a, p110b, p110d and p110c. Cancer-specific gain-of-function mutations in p110a have been identified in various malignancies. Cancer-specific mutations in the non-a isoforms of class I PI3K have not yet been identified, however overexpression of either wild-type p110b, p110c or p110d is sufficient to induce cellular transformation in chicken embryo fibroblasts. The mechanism whereby these non-a isoforms of class I mediate oncogenic signals is unknown. Here we show that potently transforming class I isoforms signal via Akt/mTOR, inhibit GSK3b and cause degradation of FoxO1. A functional Erk pathway is required for p110c and p110b transformation but not for transformation by p110d or the H1047R mutant of p110a. Transformation and signaling by p110c and p110b are sensitive to loss of interaction with Ras, which acts as a membrane anchor. Mutations in the C2 domain of p110d reduce transformation, most likely by interfering with membrane association. Several small molecule inhibitors potently and specifically inhibit the oncogenic signaling and transformation of each of the class I PI3K, and, when used in combination with MEK inhibitors, can additively reduce the transformation induced by p110b and p110c.
Introduction
The PI3K superfamily is grouped into three classes on the basis of lipid substrate specificity and sequence homology (Vanhaesebroeck et al., 1997) . Each class of PI3K is involved in distinct cellular processes and in various signal transduction pathways (Vanhaesebroeck et al., 2001) . Class I PI3K contains four isoforms of the catalytic subunit: p110a, p110b, p110d and p110g. These isoforms are further subdivided according to their regulatory subunits and connections to upstream signaling. Class IA, encompassing p110a, p110b and p110d, can be activated by receptor tyrosine kinases. These isoforms associate with the regulatory subunits p85a, p85b, p55a, p55g and p50a (Engelman et al., 2006) . Class IB, consisting of p110g, can be activated by small G-proteins and binds the regulatory subunit p101 as well as p84, and p87 PIKAP (Engelman et al., 2006) . The p110a and p110b isoforms are expressed in most tissues whereas expression of p110d and p110g is mostly restricted to cells of the hematopoietic lineage (Vanhaesebroeck et al., 2005) .
Selective knockouts in mice have been valuable in delineating the functional roles of each class I isoform in development. Knockouts of p110a and p110b are embryonic lethals (Bi et al., 1999 (Bi et al., , 2002 whereas knockouts of p110d and p110g are viable but show defects in components of the immune response (Sasaki et al., 2000; Okkenhaug et al., 2002) . However, because of the tissuespecific expression of the isoforms, the functional information that can be derived from ubiquitous knockouts is limited (reviewed in Vanhaesebroeck et al., 2005) .
Isoform-specific inhibitory antibodies have revealed intrinsic differences in the biological roles of class I isoforms expressed in the same cell: (1) p110b but not p110a is required for insulin-stimulated actin reorganization in aortic cells (Hooshmand-Rad et al., 2000) , (2) p110g but not p110a or p110b is crucial in the regulation of spontaneous Ca 2 þ spiking in cardiac cells (Bony et al., 2001) , (3) colony-stimulating factor-1 (CSF-1) induced DNA synthesis requires p110a but not p110b or p110d (Vanhaesebroeck et al., 1999) , (4) p110b or p110d but not p110a is critical for CSF-1-induced actin reorganization (Vanhaesebroeck et al., 1999) and (5) p110b but not p110d or p110a is required for apoptotic cell phagocytosis by primary macrophages (Leverrier et al., 2003) . Overexpression studies have shown that p110b but not p110a inhibits the motility of breast cancer cells (Yip et al., 2004) . All these studies suggest intrinsic differences in the function and regulation of the class I PI3K isoforms.
Recently isoform-specific inhibitors have been developed and have provided valuable tools in determining specific functions for the class I isoforms. Studies with these inhibitors support the following conclusions: (1) p110a is the primary insulin responsive PI3K in adipocytes and myotubes and is the major PI3K associated with insulin receptor substrate-1 (IRS-1) , (2) p110b contributes to the pathogenesis of arterial thrombosis (Jackson et al., 2005) , (3) p110g mediates inflammation in a model of rheumatoid arthritis (Camps et al., 2005) and (4) p110d is an essential component of neutrophil directional movement (Sadhu et al., 2003) and plays a role in cell proliferation of acute myeloid leukemia (Sujobert et al., 2005) .
Cancer-specific mutations in p110a have been identified in various human malignancies. However, no mutations in any other class I isoform have been identified. Overexpression of either p110b, p110g or p110d is sufficient to transform chicken embryo fibroblasts (CEF), suggesting an inherent oncogenic potential of these proteins . Given the different roles of the class I isoforms in normal physiology, it is likely that there are differences in the mechanism whereby each isoform induces oncogenic transformation.
Here we describe intrinsic differences in the mechanism of oncogenic signaling of non-a isoforms of p110. We also show that isoform-specific small molecule inhibitors can inhibit the transforming properties of class I isoforms and that these inhibitors can synergize with inhibitors of other signaling pathways to induce an efficient block of cellular transformation.
Results
The oncogenic signaling of wild-type class I p110 isoforms The oncogenic signaling pathway downstream of class I p110 isoforms is poorly defined. Here we sought to determine the phosphorylation status of various signaling proteins in cells transformed by different isoforms of class I PI3K.
Transformation by constitutively active chicken p110a and cancer-specific mutants of p110a has been shown to involve TOR and its downstream targets, ribosomal protein S6 kinase 70 kDa polypeptide 1 (S6K) and eukaryotic initiation factor 4E binding protein (4E-BP1) (Aoki et al., 2001; Kang et al., 2005) . Degradation of FoxO1 also occurs during transformation induced by the oncogenic myristylated chicken p110a (Aoki et al., 2004) . In CEF transformed by cancer-specific hot-spot mutants or myristylated p110a, constitutive phosphorylation of Akt (serine 473 and threonine 308), S6K (threonine 389), 4E-BP1 (serine 65) and GSK3b (serine 9) is observed ( Figure 1 ). Transformation by these hotspot mutants is also associated with degradation of FoxO1 (Figure 1 ). These results suggest that oncogenicity, whether it is derived from constitutive membrane association or from an activating mutation, correlates with increased degradation of FoxO1 and an increase phosphorylation of the following signaling molecules, Akt at serine 473 and threonine 308, S6K at threonine 389, 4E-BP1 at serine 65 and GSK3b at serine 9.
Cells transformed by either p110b or p110g do not show constitutive activation of Akt, S6K or 4E-BP1 (Figure 1 ). FoxO1 levels are reduced in p110g-transformed cells as compared to cells transfected with empty vector; however, no change in FoxO1 levels is observed in p110b-transformed cells. Conversely, CEF transformed by p110d show constitutive activation of Akt, S6K, 4E-BP and GSK3b. No FoxO1 was detected in cells transformed by p110d. This difference in the phosphorylation status of various signaling molecules in cells transformed by class I p110 isoforms reflects distinct signaling cascades specific to the p110 isoforms.
To analyse whether p110b and p110g have the ability to activate the Akt/TOR pathway, or GSK3b and to induce degradation of FoxO1, the myristylated non-a isoforms of Class I p110 were generated and evaluated. Myristylation of chicken p110a increases its oncogenicity and causes constitutive activation of Akt (Aoki et al., 2000) . Myristylation of p110b and p110g now rendered these proteins able to induce constitutive phosphorylation of Akt, S6K, 4E-BP1 and GSK3b (Figure 1 ). No FoxO1 is detected in CEF expressing any of the myristylated p110 isoforms. Myristylation of p110b and p110g caused an increase in the efficiency of oncogenic transformation compared to nonmyristylated isoforms . This increase is probably due to enhanced signaling via the Akt/TOR pathway, GSK3b and degradation or FoxO1. The observation that all isoforms signal similarly when localized to the plasma membrane but signal differently in wild-type form suggests that the class I p110 isoforms use different mechanisms to translocate to the plasma membrane. CEF were transfected with the indicated construct using the dimethylsulfoxide (DMSO)/ polybrene method. Cells were passaged three times and then lysed before western analysis. Antibodies used were phospho-Akt (pAkt) either serine 473 or threonine 308, phospho-GSK3b (pGSK3b) serine 9, GSK3b, FoxO1, phospho-S6K (p-S6K) threonine 389, S6K and phospho-4E-BP1 (p-4E-BP1) serine 65, MyrP3k (Flag), p110a, p110b, p110d and p110g (VSV-G).
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Ras acts as a membrane locator to stimulate p110g-and p110b-induced transformation Mutational inactivation of the Ras-binding domain (RBD) of p110g and p110b reduces their oncogenicity and suggests that binding to Ras is required for transformation . Ras may facilitate membrane localization of p110 isoforms similar to p85, or it may stimulate the kinase activity of p110. To test whether Ras binding recruits p110 to the plasma membrane, wild-type and the Ras-binding domain mutants p110g and p110b were myristylated and transfected into CEF. All four constructs induced oncogenic transformation with equal efficiency (Figure 2 ). The mutations in the Ras-binding domain also did not affect the kinase activity of p110g or p110b (data not shown). However, the myristylated RBD mutants of p110g and p110b induced a lower level of Akt phosphorylation at serine 473 and threonine 308 than the myristylated wild-type proteins. Interestingly, there was no difference between myristylated wild-type and myristylated RBD mutants in the phosphorylation of S6K, GSK3b and 4E-BP1 (Figure 2 ). The level of FoxO1 degradation was also similar in cells expressing myristylated wild-type and RBD mutants p110g and p110b. Equal levels of oncogenic transformation by the myristylated constructs could therefore reflect similar activation of downstream Akt targets. There was no change in the level of ERK (extracellular signal-regulated kinase), MEK (mitogen-activated protein kinase kinase 1) or Raf (v-raf-leukemia viral oncogene 1) phosphorylation in cells expressing either wild-type or RBD mutants p110g or p110b, suggesting Oncogenic signaling of class I PI3K isoforms A Denley et al that PI3K does not alter the MAPK (mitogen-activated protein kinase) pathway via Ras (data not shown). Our findings document an effect of Ras on PI3K-mediated phosphorylation of Akt. However, the primary role of Ras in PI3K-induced oncogenic transformation is most likely to locate the p110 to the plasma membrane.
Basic residues within the C2 domain of p110d are critical for transformation PI3K can be recruited to the membrane via several different mechanisms. The C2 domain of the catalytic subunit of class I PI3K has been shown to confer the ability to bind the plasma membrane, and an isolated C2 domain of PI3K can interact with phospholipid vesicles (Walker et al., 2000) . Given that p110d does not rely on interaction with Ras for membrane recruitment, we investigated the potential roles of the basic residues within the C2 domain of p110d in transformation and membrane localization. Sequence alignment of the class I PI3K isoforms reveals many basic residues, mostly lysines, within the C2 domain. Basic residues are known to be involved in lipid-protein interactions (Heo et al., 2006 ). An area of concentrated basic residues in the C2 domain of p110d, containing three lysines, that is, K402, K409 and K410, is not observed in any other class I isoform. We mutated these lysines to alanine individually and in combination and examined the transforming ability of the mutants. Mutation of any of the three lysines alone had minimal effect on transformation. However, when all three lysine residues were mutated, almost complete inhibition of focus formation in CEF was observed ( Figure 3 ). This reduction in transformation was correlated with a reduction in the phosphorylation level of Akt at serine 473 ( Figure 3 ).
Transformation by p110g and p110b is inhibited by the Raf inhibitor BAY 43-9006 (Sorafenib) and the MEK1/2 inhibitor UO126 It has been reported previously that p110g can phosphorylate MEK1, which leads to phosphorylation and activation of Erk (Bondeva et al., 1998) . Transformation by p110g may therefore involve the Erk pathway. To test this possibility, cellular transformation by class I PI3K isoforms was determined in the presence of the MEK1/2 inhibitor UO126. Focus formation by p110g and p110b was decreased 10-fold in the presence 10 mM UO126 compared to controls without inhibitor. No Erk phosphorylation was detected in CEF transfected with any PI3K isoform and treated with 10 mM UO126. A downstream phosphorylation target of Erk is ribosomal protein S6 kinase, that is, 90 kDa, polypeptide 1 (p90rsk), which after phosphorylation can then activate the transcription factor CREB (Chang et al., 2003) . In the presence of UO126 the phosphorylation of p90rsk at serine 380 was abolished, suggesting complete inhibition of both Erk and its downstream targets (Figure 4 ). The level of Akt phosphorylation at serine 473 was unaffected by UO126 showing that the effect of MEK blockade on transformation was due to a reduction in signaling via the Erk signaling and not by off target inhibition of Akt (data not shown). These results suggest that p110g and p110b require a functional Erk pathway for transformation while the focus forming efficiencies of the cancer specific mutant p110aH1047R and of p110d are not affected, although a modest decrease in the size of individual foci was observed with p110d. To confirm the requirement for Erk signaling in p110g and p110b transformation, we tested the effect of the Raf inhibitor, BAY 43-9006 (Sorafenib). Raf phosphorylates MEK1 on serines 218 and 222 and regulates its biological activity (Zheng and Guan, 1994) . BAY 43-9006 prevents the phosphorylation of MEK1 at these sites and decreases the levels of Erk activity downstream of MEK (Lyons et al., 2001) . Focus formation induced by p110g and p110b, but not by p110d or Myr-P3k, was inhibited by BAY 43-9006 ( Figure 5 ). No Erk phosphorylation was detected in CEF transfected with any PI3K isoform and treated with 2.5 mM BAY 43-9006. However, Akt phosphorylation was unaffected (data not shown). These observations suggest that Raf is involved in transformation by p110g and p110b and support the conclusion that the Erk pathway is required for the transformation by these PI3K isoforms. The data reveal the potential of several components of the Erk pathway as therapeutic targets for treating tumors with elevated p110b or p110g signaling.
Inhibition of class I PI3K isoforms by isoform-specific inhibitors
Recently isoform-specific small-molecule inhibitors have been described for p110b (Jackson et al., 2005) , p110d (Sadhu et al., 2003) and p110g (Camps et al., 2005) . These compete with ATP and inhibit the kinase activity of the catalytic subunit. We investigated the potency and Oncogenic signaling of class I PI3K isoforms A Denley et al specificity of these inhibitors in cell transformation assays of the PI3K isoforms. The p110b-specific inhibitor TGX-221 inhibited p110b in a dose-dependent manner with an approximate IC 50 of 40 nM (Figure 6 ). It did not reduce the efficiency of transformation of other PI3K isoforms or of the v-Src oncoprotein. Besides completely inhibiting p110b-induced transformation, TGX-221, at a concentration of 250 nM, also interfered with Myrp110b-induced phosphorylation of Akt at serine 473 and threonine 308. It also reduced the phosphorylation levels of S6K and caused a slight stabilization of FoxO1. Neither GSK3b nor 4E-BP1 phosphorylation levels were affected by TGX-221 at 250 nM (Figure 9 ). The expression of p110b was unaffected by TGX-221, suggesting that the effect on transformation and on signaling was due to inhibition of p110b kinase activity.
The p110d-specific inhibitor IC87114 was effective against p110d-induced transformation with an IC 50 of approximately 750 nM. At a concentration of 5 mM, IC87114 completely abrogated p110d-induced transformation and p110d-induced Akt phosphorylation but did not affect the transforming ability or signaling of other PI3K isoforms or of the v-Src oncoprotein control, (Figure 7 ). The inhibition of p110d by IC87114 led to a stabilization of FoxO1 and a decrease in GSK3b phosphorylation ( Figure 9 ). Phosphorylation of S6K at threonine 389 and 4EBP-1 at serine 65 was also completely abrogated by IC87114 (Figure 9 ). The expression of p110d was unaffected by this inhibitor.
The p110g inhibitor AS-604850 was effective against p110g-induced transformation with an IC 50 of approximately 2 mM, while it had no effect on the focus-forming ability of other PI3K isoforms (Figure 8) . At a concentration of 5 mM, which almost completely blocked cell transformation, the level of Akt phosphorylation at serine 473 and threonine 308 was decreased but still 
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A Denley et al detectable ( Figure 9 ). However, this inhibitor did affect Akt activation by p110b and p110d at concentrations that did not inhibit cellular transformation by these isoforms. FoxO1 was not stabilized, most likely due to the incomplete inhibition of Akt.
Additive Inhibition of transformation by isoform-specific inhibitors and UO126 As described above, transformation induced by p110b and p110g is sensitive to inhibition of MEK 1/2 by UO126, while p110d is not. We investigated whether UO126 could increase the potency of the p110b-specific inhibitor TGX-221 or the p110g-specific inhibitor AS-604850 by determining the efficiencies of transformation induced by p110b and p110g in the presence of PI3K and MEK inhibitors. The efficacy of the b-and g-isoform-specific inhibitors was greatly enhanced in the presence of UO126 (Figure 10 ). In contrast, the efficacy of focus inhibition by the p110d-specific inhibitor IC87114 was not increased in the presence of UO126. 
Discussion
The oncogenic potential of class I PI3K was revealed in studies of the avian retrovirus ASV16, which carries the coding sequence of p110a as an oncogene. Analysis of ASV16 in cell culture identified kinase activity and constitutive localization at the plasma membrane as essential components of p110a oncogenicity. The discovery of cancer-specific gain-of-function mutations in PIK3CA, the human gene coding for 110a, has identified this lipid kinase as a potential therapeutic target for several human cancers. p110a needs to be mutated to become oncogenic. In contrast, the non-a isoforms of class I PI3K, p110b, p110g and p110d, have an inherent oncogenic activity as wild-type proteins. This observation is in accord with evidence showing that p110d and p110g are involved in the development and progression of malignancies, such as acute and chronic myeloid leukemia (Skorski et al., 1995 (Skorski et al., , 1997 Klejman et al., 2002; Min et al., 2003; Kharas et al., 2004; Kubota et al., 2004; Grandage et al., 2005; Sujobert et al., 2005; Hickey and Cotter, 2006; Martelli et al., 2006; Billottet et al.) . Recent structural studies have advanced our understanding of the mechanisms that mediate the gain of function in cancer-specific mutations of p110a (Miled et al., 2007) . But our knowledge of the oncogenic signals emanating from all class I PI3K isoforms is sketchy, and increasing this knowledge is crucial to designing effective chemotherapeutic treatments aimed at perturbing isoform-specific functions. The goal of this study was to shed light on critical aspects of PI3K signaling and to highlight unique potential therapeutic nodes in the pathways emanating from the various PI3K isoforms. The specific functions of the non-a class I PI3K isoforms in normal physiology suggested that the mechanism of transformation induced by these oncoproteins could be different. Oncogenic signaling of p110d and of cancer-specific mutants p110a is correlated with constitutive activation of Akt (Kang et al., 2005) . However, the p110g isoform activates Akt only conditionally, whereas p110b does not mediate detectable phosphorylation of Akt (Zhao et al., 2005; Kang et al., 2006) . As a measure of Akt activity linked to signaling from the class I p110 isoforms, we analysed the phosphorylation levels of direct Akt substrates GSK3b and FoxO1 in transfected CEF. GSK3b is a proapoptotic kinase (Mulholland et al., 2006) and also negatively regulates the cell cycle (Dong et al., 2005) . GSK3b is phosphorylated by Akt at serine 9 and consequently inactivated (Shaw et al., 1997) . FoxO1 is a transcriptional regulator that controls the expression of several genes involved in cell proliferation, including p21
Cip1 (Seoane et al., 2004) and cyclin D2 (Bouchard et al., 2004) . FoxO1 is phosphorylated by Akt on threonine 24 and serine 253 which then results in nuclear exclusion (Biggs et al., 1999; Brunet et al., 1999) . Degradation of FoxO1 has been observed in PI3K-and Akt-transformed cells (Aoki et al., 2004) . Constitutive phosphorylation of GSK3b and degradation of FoxO1 suggested a high level of Akt activity in CEF transfected with cancer-specific mutants of p110a and wild-type p110d. CEF expressing p110b and p110g did not show elevated GSK3b phosphorylation. However, some slight decrease in FoxO1 levels was observed. These observations raise the question of whether oncogenic cellular transformation by p110b and p110g is Akt-independent. The fact that the oncogenicity of p110b and p110g is sensitive to rapamycin argues against this possibility. However, more experiments with dominant negative Akt are needed for a more definitive answer.
Constitutive membrane localization of p110a by a myristylation signal or viral gag protein activates oncogenic capacity that is not apparent in the wild-type protein (Chang et al., 1997; Aoki et al., 2000) . Adding a myristylation signal to wild-type p110b and p110g likewise increases the oncogenicity of these isoforms. However, addition of a myristylation signal to p110d has no substantial effect on its ability to induce cell transformation . The increase in oncogenicity of myristylated p110b and p110g is associated with increased phosphorylation of Akt and an increased phosphorylation of several signaling molecules downstream of Akt including GSK3b, p70s6K and 4E-BP1. No change in Akt phosphorylation and Akt activity toward its substrates is observed in CEF transfected with myristylated p110d in comparison to cells transfected with wild-type p110d. These observations suggest that maximal oncogenic signaling of class I PI3K isoforms is correlated with activation of Akt (TOR, S6K, 4-EBP1) and consequent inactivation of GSK3b and FoxO1.
We had reported previously that interaction with Ras is a requirement for p110g-and p110b-induced transformation . These findings are supported by evidence demonstrating that input from Ras is required for maximal p110g and Drosophila p110 signaling (Orme et al., 2006; Suire et al., 2006) . For the oncogenic activity of p110a in mice, binding to Ras has Figure 9 PI3K isoform-selective inhibitors affect signaling downstream of their desired target isoform. (a) Cells transfected with either RCAS(A) alone or RCAS(A) containing coding sequences for the indicated p110 were passaged three times to allow complete retroviral infection. Transfected cells were incubated in low serum for 24 h then incubated for 2 h in serum-free media containing 250 nM TGX-221. Cells were then lysed, and the total protein or phosphorylation state of several signaling molecules was analysed by western blotting. (b) Cells transfected with either RCAS(A) alone or RCAS(A) containing coding sequences for the indicated p110 were passaged three times to allow complete retroviral infection. Transfected cells were incubated in low serum for 24 h, then incubated for 2 h in serum-free media containing 5 mM IC87114. Cells were then lysed, and the total protein or phosphorylation state of several signaling molecules was analysed by western blotting. (c) Cells transfected with either RCAS(A) alone or RCAS(A) containing coding sequences for the indicated p110 were passaged three times to allow complete retroviral infection. Transfected cells were incubated in low serum for 24 h then incubated for 2 h in serum-free media containing 5 mM AS-604850. Cells were then lysed, and the total protein or phosphorylation state of several signaling molecules was analysed by western blotting.
recently been shown to be essential (Gupta et al., 2007) . Here we characterize the nature of the requirement for Ras by showing that constitutively membrane-localized p110g and p110b do not require an interaction with Ras for full oncogenic activity. This finding suggests that Ras acts as a membrane anchor for p110g and p110b. Figure 10 Additive inhibition induced by UO126 and isoform-specific PI3K inhibitors. (a) CEF were transfected with RCAS(A) containing the sequence encoding human p110b and overlaid every other nutrient agar containing TGX-221 alone (upper wells) or in combination with 5 mM UO126 (lower wells). Shown is a representative focus assay. The number of foci in each well was counted from three independent experiments and the data graphed ± s.e.m. (b) CEF were transfected with RCAS(A) containing the sequence encoding human p110g and overlaid every other day with nutrient agar containing AS-604850 alone (upper wells) or in combination with 5 mM UO126 (lower wells). Shown is a representative focus assay. The number of foci in each well was counted from three independent experiments and the data graphed±s.e.m. (c) CEF were transfected with RCAS(A) containing the sequence encoding human p110d and overlaid every other day with nutrient agar containing IC87114 alone (upper wells) or in combination with 5 mM UO126 (lower wells). Shown is a representative focus assay. The number of foci in each well was counted from three independent experiments and the data graphed ± s.e.m.
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However, Ras appears to play a dual role in p110g and p110b function, because myristylation of the Rasbinding domain mutants of p110g and p110b does not allow full activation of Akt, even though it restores transforming potential. Therefore, both p110g and p110b require activation by Ras to mediate full Akt phosphorylation. Interestingly, despite the lower level of Akt activation by membrane localized Ras-binding domain mutants of p110g or p110b, Akt substrates were phosphorylated at levels comparable to those achieved by the wild-type isoforms. This lack of correlation between Akt phosphorylation and the phosphorylation of Akt targets requires further study. The C2 domain is a domain module that facilitates recruitment of p110 to the plasma membrane (Nalefski and Falke, 1996; Newton and Johnson, 1998; Rizo and Sudhof, 1998) . All isoforms of class I p110 contain a C2 domain. The C2 domain in p110g has also been shown to mediate recruitment to membranes (Walker et al., 2000) . Positively charged amino acids are critically involved in membrane binding (Heo et al., 2006) . Several cancerspecific mutations in the C2 domain of p110a result in a change to a positive charge, that is, N345K, C378R, E418K, C420R and E453K (Campbell et al., 2004; Samuels et al., 2004; Saal et al., 2005) . Both N345K and C420R mutations cause the protein to exhibit gain of function and oncogenicity (Gymnopoulos et al., 2007) . The oncogenicity of these C2 domain mutants may be facilitated by their more efficient localization to the plasma membrane (Gymnopoulos et al., 2007) . Our findings showing that positive charges unique to the C2 domain of p110d are required for normal function support an essential role of this domain in the recruitment to the plasma membrane. They also suggest distinct isoform-specific modes of membrane localization.
The data presented here reveal a novel requirement for the ERK pathway in p110g-and p110b-induced oncogenic transformation. This requirement suggests that inhibitors of Raf, MEK or ERK may be therapeutically effective in the treatment of tumors with elevated p110g and p110b. The requirement for both the ERK and PI3K pathways has been reported previously for the potent transformation of the FL5.12 hematopoetic cell line (McCubrey et al., 2001) . Furthermore, MEK1-mediated growth of FDC-P1 leukemia cells depends on a functional PI3K . Our results suggest that BAY 43-9006 (Sorafenib), a kinase inhibitor approved for treatment of advanced renal cell carcinoma, may provide a new avenue for combination therapy with inhibitors of the PI3K pathway in tumors with elevated p110b and p110g signaling.
We have reported previously that rapamycin, an inhibitor of TOR, interferes with p110g-and p110b-induced oncogenic transformation . Inhibition of TOR relieves a negative feedback loop that targets IRS-1 and leads to elevated phosphorylation of Akt. Removal of this negative feedback may underlie the poor clinical responses of cancer patients treated with rapamycin (Haruta et al., 2000; Sun et al., 2005; O'Reilly et al., 2006) . Combined inhibition of PI3K and TOR is more effective in reducing cancer cell growth than inhibition of either target alone (Sun et al., 2005; Fan and Weiss, 2006; . Our results suggest that inhibitors of the Erk pathway could complement inhibitors of PI3K and could serve as a substitute for rapamycin in blocking the growth of cancer cells that show high levels of p110g and p110b.
Isoform-specific PI3K inhibitors have become of great interest recently because of their therapeutic potential Hawkins et al., 2006; Vogt et al., 2006) . Newly identified inhibitors which all compete with ATP for binding to the kinase active site have been useful tools in elucidating the role of p110 isoforms in various pathologies such as growth and metabolic regulation , asthma (Ali et al., 2004) , inflammation (Barber et al., 2005) , arthritis (Camps et al., 2005) and thrombosis (Jackson et al., 2005) . Our data show that isoform-specific inhibitors can block the oncogenicity of class I PI3Ks. Inhibitors of p110b, p110d and p110g are all effective at interfering with cellular transformation and are highly selective for the targeted isoform. These observations offer promise that small, isoform-specific molecules, acting in a cellular context, will provide clinical benefits in diseases that involve deregulated PI3K signaling.
In summary, data in this report show that oncogenic signaling of different class I p110 isoforms is distinct and reveals novel avenues for therapeutic intervention.
Materials and methods

Reagents and inhibitors
TGX-221 and AS-604850 were purchased from Cayman Chemicals (Ann Arbor, MI, USA). IC87114 was received from ICOS Corporation (Bothwell, WA, USA). UO126 was purchased from Calbiochem (San Diego, CA, USA).
Cell culture
Primary cultures of CEF were prepared from White Leghorn embryos purchased from Charles River Breeding Laboratories (Preston, CT, USA). Each transfection with DNA or infection with avian retrovirus was performed with newly prepared CEF. CEF were routinely cultured in F-10.
Plasmid construction
All wild-type and myristylated class I PI3K isoform constructs, as well as p110g K255E and p110b K230E, were described previously . Briefly, p110b K230E was amplified with primers b-5 0 -Mlu (5 0 -TGTGGAACGCGTT GCTTCAGTTTCATAATGCC-3 0 ) and b-3 0 -Hind (5 0 -ACATTA GGAGCGAAGCTTGATCGTTAAGATCTG-3 0 ) and p110g K255E was amplified with g-5 0 -Mlu (5 0 -CTACTGACGCGTGA GCTGGAGAACTATAAACAGC-3 0 ) and g-3 0 -Sal (5 0 -AACT TGTTTTTGATTGTCGACTAAAGTATTAGGCTG-3 0 ). Amplified p110b K230E and p110g K255E were then cloned into the MluI/HindIII or MluI/SalI site of the MyrpBSFI vector, respectively. The protein kinase-only mutant of p110g was also previously described (Bondeva et al., 1998) . Myristylated protein kinase-only p110g was produced using the same method as for p110g K255E. All PI3K coding sequences were ultimately cloned into the avian retroviral vector RCAS.Sfi, a modified version of RCAS (Aoki et al., 1998) . The p110 isoforms used in this study were overexpressed without co-expression of the regulatory subunits of class I PI3K. Avian cells contain high levels of p85 and possibly also of p101, which would be available for dimerization with p110.
Focus assays
For focus assays CEF were infected with RCAS virus containing the relevant oncogene as previously described (Bos et al., 1990) . Cells were fed nutrient agar every other day and then stained with crystal violet to visualize the foci of transformed cells. Inhibitors were prepared in 100% dimethylsulphoxide (DMSO) and added at the desired concentration to the nutrient agar overlays. An equivalent amount of 100% DMSO was added to cells as a control.
Western analysis
Cell lysates were prepared from CEF that had been transfected with DNA using the DMSO/polybrene method (Kawai and Nishizawa, 1984) . For serum starvation, subconfluent cultures were kept in Ham's F-10 medium with 0.5% FCS and 0.1% chicken serum for 40 h prior to 2 h of starvation in F-10 Ham's medium alone. Inhibitors or DMSO were added at the appropriate concentration during the final 2 h in serum-free F-10 Ham's medium. Western blotting was performed as previously described by Aoki et al. (2000) and Kang et al. (2005 Kang et al. ( , 2006 . Abbreviations 4E-BP, eukaryotic initiation factor 4E binding protein; Akt, cellular homolog of murine thymoma virus akt8 oncogene; ASV16, avian sarcoma virus 16; CEF, chicken embryo fibroblasts; eIF4E, eukaryotic initiation factor 4E; Erk, extracellular signal-regulated kinase; FOXO, forkhead box O transcription factor; GSK3b, glycogen synthase kinase-3-beta; MAPK, mitogen-activated protein kinase; MEK, mitogenactivated protein kinase kinase 1; p70S6K, ribosomal protein S6 kinase, 70 kDa, polypeptide 1; p90rsk, ribosomal protein S6 kinase, 90 kDa, polypeptide 1; PI3K, phosphatidylinositol 3-kinase; Raf, v-raf-leukemia viral oncogene 1; Ras, rat sarcoma viral oncogene; RBD, Ras-binding domain; S6, S6 ribosomal protein; TOR, target of rapamycin.
